EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1

Albert Guinart-Cuadra iD, Aida Piedra iD, Sergio Martínez-Recio iD, Maria Mulet iD, Carlos Zamora, Rubén Osuna-Gómez iD, Elisabet Cantó, Maria Angels Ortiz iD, Andrés Barba, Judit Sanz-Beltran iD, Jorgina Serra-López iD, Luís Paz-Ares und 8 weitere

International Journal of Molecular Sciences · 13.07.2026 · 27 (14) · 6225

DOI: 10.3390/ijms27146225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.07.2026. Verfasst von Albert Guinart-Cuadra und 19 weiteren Autor:innen. Beteiligte Einrichtung: Group of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Biomarkers, Tumor, Lung Neoplasms, B7-H1 Antigen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca (Spain).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Soluble immune checkpoints (sICs) have emerged as potential biomarkers in various cancers. However, their role in extensive-stage small cell lung cancer (ES-SCLC), an aggressive tumor type with limited therapeutic options and poor prognosis, remains poorly characterized. We analyzed 14 circulating sICs, leukocyte–platelet (PLT) complexes, and PD-L1 surface expression in ES-SCLC patients treated with chemoimmunotherapy (n = 41) prior to treatment and healthy donors (HD, n = 10). We assessed their associations with clinical and demographic factors and performed survival analyses using Kaplan–Meier and log-rank tests. Levels of soluble (s) PD-L1, PD-L2, BTLA, HVEM, TIM-3, and CD27 were higher in plasma from ES-SCLC patients compared to those from HD (p < 0.05). Patients with liver metastases exhibited higher sIC levels, and a multivariate model demonstrated discriminative power. Network analyses revealed distinct patterns of immune dysregulation between ES-SCLC and HD. We observed correlations among sICs and leukocyte–PLT complexes and leukocyte PD-L1 expression, indicating links between systemic immune status and tumor–immune interactions. Furthermore, increased concentrations of sTIM-3, sCD27, sHVEM and sPD-L1 were associated with a poor prognosis. Overall, sICs reflect relevant clinical, prognostic, and immunological features in ES-SCLC. Their plasma measurement could aid in non-invasive patient stratification regarding liver metastases and survival risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaBiomarkers, TumorLung NeoplasmsB7-H1 AntigenImmune Checkpoint ProteinsImmune Checkpoint InhibitorsHumansFemalePrognosisMaleMiddle AgedAged

Stichwörter der Autor:innen

extensive-stage small cell lung cancerprognostic biomarkerssoluble immune checkpoints

Substanzen

Biomarkers, TumorB7-H1 AntigenCD274 protein, humanImmune Checkpoint ProteinsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Group of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.
  • Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, 08193 Bellaterra, Spain.
  • Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Department of Medicine, Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
  • Medical Oncology Department, Hospital Universitario 12 Octubre, 28041 Madrid, Spain.
  • Medical Oncology Department, Hospital del Mar-CIBERONC, 08003 Barcelona, Spain.

ORCID-Profile: Albert Guinart-Cuadra, Aida Piedra, Sergio Martínez-Recio, Maria Mulet, Rubén Osuna-Gómez, Maria Angels Ortiz, Judit Sanz-Beltran, Jorgina Serra-López, Edurne Arriola, Alberto Luis Moreno, Dolores Isla, Margarita Majem, Silvia Vidal

Förderung

  • AstraZeneca (Spain)

Zitieren

APA

Guinart-Cuadra, A., Piedra, A., Martínez-Recio, S., Mulet, M., Zamora, C., Osuna-Gómez, R., Cantó, E., Ortiz, M. A., Barba, A., Sanz-Beltran, J., Serra-López, J., Paz-Ares, L., Arriola, E., Moreno, A. L., Garcia-Campelo, R., Martí-Blanco, C., Isla, D., Callejo, Á., Majem, M., & Vidal, S. (2026). Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1. International Journal of Molecular Sciences, 27(14), 6225. https://doi.org/10.3390/ijms27146225

Vancouver

Guinart-Cuadra A, Piedra A, Martínez-Recio S, Mulet M, Zamora C, Osuna-Gómez R, et al. Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1. International Journal of Molecular Sciences. 2026;27(14):6225. doi:10.3390/ijms27146225

BibTeX
@article{GuinartCuadra2026,
  author = {Guinart-Cuadra, Albert and Piedra, Aida and Martínez-Recio, Sergio and Mulet, Maria and Zamora, Carlos and Osuna-Gómez, Rubén and Cantó, Elisabet and Ortiz, Maria Angels and Barba, Andrés and Sanz-Beltran, Judit and Serra-López, Jorgina and Paz-Ares, Luís and Arriola, Edurne and Moreno, Alberto Luis and Garcia-Campelo, Rosario and Martí-Blanco, Cristina and Isla, Dolores and Callejo, Ángel and Majem, Margarita and Vidal, Silvia},
  title = {Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6225},
  doi = {10.3390/ijms27146225}
}
Kostenlos starten →